However, fb-PMT inhibited the uptake of rosuvastatin by both OATP1B1 and OATP1B3 with IC s >3 and <10 μM. In summary, data suggest that the systemic administration of fb-PMT is unlikely to lead to DDIs through CYP enzymes or ABC and SLC transporters in humans.
over 1 year ago
Preclinical • Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)